CAR-T strategies targeting ROR1+ cancer cells have also been developed and shown to have limited toxicity in primates and should be efficacious in eradicating ROR1+ CLL [24], but CAR-T efficacy in solid cancers generally has yet to be established. The gene discussed is ROR1; the disease is B-cell chronic lymphocytic leukemia.